{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T08:57:06Z","timestamp":1776934626755,"version":"3.51.2"},"reference-count":61,"publisher":"Informa UK Limited","issue":"8","funder":[{"name":"Pharmaceutical Toxicology"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2025,8,3]]},"DOI":"10.1080\/14740338.2024.2386371","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T06:24:33Z","timestamp":1722234273000},"page":"937-948","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Disproportionality analysis of data from VigiBase and other global product safety databases on toxicity of iron chelating agents"],"prefix":"10.1080","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6767-9092","authenticated-orcid":false,"given":"Burcu Eda","family":"Arda","sequence":"first","affiliation":[{"name":"Yeditepe University Faculty of Pharmacy","place":["Istanbul, Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6482-3143","authenticated-orcid":false,"given":"Hande","family":"Sipahi","sequence":"additional","affiliation":[{"name":"Yeditepe University Faculty of Pharmacy","place":["Istanbul, Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"e_1_3_9_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7360-6"},{"key":"e_1_3_9_4_1","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2016.069"},{"issue":"4","key":"e_1_3_9_5_1","first-page":"241","article-title":"Management of iron deficiency anemia","volume":"11","author":"Jimenez K","year":"2015","unstructured":"Jimenez K, Kulnigg-Dabsch S, Gasche C. Management of iron deficiency anemia. Gastroenterol Hepatol (NY). 2015 Apr;11(4):241\u2013250. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27099596","journal-title":"Gastroenterol Hepatol (NY)"},{"key":"e_1_3_9_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0b013e32834be6fd"},{"key":"e_1_3_9_7_1","unstructured":"Thalassemia. Available from: https:\/\/www.mayoclinic.org\/diseases-conditions\/thalassemia\/symptoms-causes\/syc-20354995"},{"key":"e_1_3_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7091-3909-7"},{"key":"e_1_3_9_9_1","unstructured":"Myelodysplastic syndromes. Available from: https:\/\/www.mayoclinic.org\/diseases-conditions\/myelodysplastic-syndrome\/symptoms-causes\/syc-20366977"},{"issue":"2","key":"e_1_3_9_10_1","first-page":"164","article-title":"Review on iron and its importance for human health","volume":"19","author":"Abbaspour N","year":"2014","unstructured":"Abbaspour N, Hurrell R, Kelishadi R. Review on iron and its importance for human health. J Res Med Sci. 2014 Feb;19(2):164\u2013174.","journal-title":"J Res Med Sci"},{"key":"e_1_3_9_11_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0606424103"},{"key":"e_1_3_9_12_1","unstructured":"Yuen H Becker W. StatPearls [internet]. Treasure Island (FL): StatPearls Publishing; Iron Toxicity. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459224\/"},{"key":"e_1_3_9_13_1","unstructured":"O\u2019Malley G O\u2019Malley R. Iron Poisoning [Internet]. Available from: https:\/\/www.merckmanuals.com\/home\/injuries-and-poisoning\/poisoning\/iron-poisoning"},{"key":"e_1_3_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02982791"},{"key":"e_1_3_9_15_1","doi-asserted-by":"publisher","DOI":"10.5005\/jp-journals-10071-23307"},{"key":"e_1_3_9_16_1","first-page":"372","volume-title":"Chelation therapy in the treatment of metal intoxication","author":"Aaseth J","year":"2016","unstructured":"Aaseth J, Crisponi G, Anderson O, editors. Chelation therapy in the treatment of metal intoxication. Oxford: Elsevier; 2016. p. 372. Roskilde University, Department of Science and Environment, Denmark."},{"key":"e_1_3_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.3.739"},{"key":"e_1_3_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24479"},{"key":"e_1_3_9_19_1","unstructured":"FDA adverse events reporting system (FAERS) public dashboard Available from: https:\/\/fis.fda.gov\/sense\/app\/d10be6bb-494e-4cd2-82e4-0135608ddc13\/sheet\/7a47a261-d58b-4203-a8aa-6d3021737452\/state\/analysis"},{"key":"e_1_3_9_20_1","unstructured":"Database of Adverse Event Notifications (DAEN). Available from: https:\/\/www.tga.gov.au\/database-adverse-event-notifications-daen"},{"key":"e_1_3_9_21_1","unstructured":"Eudravigilance - European database of suspected adverse drug reaction reports [internet]. Available from: http:\/\/www.adrreports.eu\/en\/search.html"},{"key":"e_1_3_9_22_1","unstructured":"Center UM. What is a signal? Available from: https:\/\/www.who-umc.org\/research-scientific-development\/signal-detection\/what-is-a-signal\/"},{"key":"e_1_3_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ailsci.2021.100005"},{"key":"e_1_3_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04037.x"},{"key":"e_1_3_9_25_1","unstructured":"WHO. UMC. Available from: https:\/\/who-umc.org\/vigibase\/"},{"key":"e_1_3_9_26_1","unstructured":"UMC. Access the leading source of global safety data. Available from: https:\/\/who-umc.org\/vigibase\/vigibase-services\/"},{"key":"e_1_3_9_27_1","unstructured":"FDA. Archived reports | potential signals of serious Risks\/New safety information identified from the FDA adverse event reporting system (FAERS) (formerly AERS). Available from: https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/archived-reports-potential-signals-serious-risksnew-safety-information-identified-fda-adverse-event"},{"key":"e_1_3_9_28_1","unstructured":"Center UM. VigiBase: WHO\u2019s global database signalling harm and pointing to safer use."},{"key":"e_1_3_9_29_1","unstructured":"FDA. Potential signals of serious Risks\/New safety information identified from the FDA adverse event reporting system (FAERS) Available from: https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/potential-signals-serious-risksnew-safety-information-identified-fda-adverse-event-reporting-system"},{"key":"e_1_3_9_30_1","unstructured":"EMA. PRAC recommendations on safety signals. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/pharmacovigilance\/signal-management\/prac-recommendations-safety-signals#list-of-safety-signals-discussed-since-september-2012-section"},{"key":"e_1_3_9_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocv063"},{"key":"e_1_3_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1875-5364(13)60035-7"},{"key":"e_1_3_9_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1002"},{"key":"e_1_3_9_34_1","unstructured":"Center UM. Statistical reasoning and algorithms in pharmacovigilance."},{"key":"e_1_3_9_35_1","unstructured":"Chiesi. Highlights of prescribing information: ferriprox. 2020 May."},{"key":"e_1_3_9_36_1","volume-title":"Highlights of prescribing information","author":"Novartis","year":"2022","unstructured":"Novartis. Highlights of prescribing information. New Jersey (USA): Desferal; 2022."},{"key":"e_1_3_9_37_1","volume-title":"Highlights of prescribing information","author":"Novartis","year":"2020","unstructured":"Novartis. Highlights of prescribing information. New Jersey (USA): Exjade; 2020."},{"key":"e_1_3_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(01)90061-7"},{"key":"e_1_3_9_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.4.1229.004k32_1229_1236"},{"key":"e_1_3_9_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.3365.3365"},{"key":"e_1_3_9_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb03318.x"},{"key":"e_1_3_9_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10616-013-9617-8"},{"key":"e_1_3_9_43_1","doi-asserted-by":"publisher","DOI":"10.1159\/000203853"},{"key":"e_1_3_9_44_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-1824"},{"issue":"1","key":"e_1_3_9_45_1","first-page":"345","article-title":"Cerebral and ocular toxicity induced by Desferrioxamine","volume":"56","author":"Blake DR","unstructured":"Blake DR, Winyard P, Lunec J, et al. Cerebral and ocular toxicity induced by Desferrioxamine. QJM: An Int J Med. 1985 Jul 1;56(1):345\u2013355.","journal-title":"QJM: An Int J Med"},{"key":"e_1_3_9_46_1","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.98714"},{"key":"e_1_3_9_47_1","first-page":"400","volume-title":"33 - cardiac iron loading and myocardial T2*","author":"Westwood MA","year":"2019","unstructured":"Westwood MA, Pennell DJ. 33 - cardiac iron loading and myocardial T2*. In: Manning WJ, Pennell DJBTCMR ,Third E, editors. Philadelphia: Elsevier; 2019. p. 400\u2013409."},{"key":"e_1_3_9_48_1","first-page":"1","article-title":"Review of oral iron chelators (deferiprone and deferasirox) for the treatment of iron overload in pediatric patients","author":"Algren DA","year":"2010","unstructured":"Algren DA. Review of oral iron chelators (deferiprone and deferasirox) for the treatment of iron overload in pediatric patients. World Health Organ [Online]. 2010:1\u201322.","journal-title":"World Health Organ [Online]"},{"key":"e_1_3_9_49_1","unstructured":"Guarin GE. What is the role of iron chelation therapy in the treatment of transfusion-induced iron overload? [Internet]. 2020. Available from: https:\/\/www.medscape.com\/answers\/1389732-177349\/what-is-the-role-of-iron-chelation-therapy-in-the-treatment-of-transfusion-induced-iron-overload"},{"key":"e_1_3_9_50_1","unstructured":"EXJADE\u00ae (deferasirox). 2007. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/021882s002lbl.pdf"},{"key":"e_1_3_9_51_1","unstructured":"FDA. Drugs@FDA: FDA-Approved Drugs [Internet]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=016267"},{"key":"e_1_3_9_52_1","unstructured":"FDA. Drugs@FDA: FDA-Approved Drugs."},{"issue":"1","key":"e_1_3_9_53_1","first-page":"116","article-title":"Gender differences in the prevalence and severity of bone disease in thalassaemia","volume":"6","author":"Kyriakou A","unstructured":"Kyriakou A, Savva S, Savvides I, et al. Gender differences in the prevalence and severity of bone disease in thalassaemia. Pediatr Endocrinol Rev. 2008 Nov 1;6(Suppl 1):116\u2013122.","journal-title":"Pediatr Endocrinol Rev"},{"key":"e_1_3_9_54_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.28220"},{"key":"e_1_3_9_55_1","unstructured":"FDA. Recalls market withdrawals & safety alerts [Internet]. Available from: https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts"},{"key":"e_1_3_9_56_1","unstructured":"EMA. Product defects and recalls. Available from: https:\/\/www.ema.europa.eu\/en\/veterinary-regulatory\/post-authorisation\/compliance\/product-defects-recalls"},{"key":"e_1_3_9_57_1","unstructured":"Ferriprox - Summary of the risk management plan. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/ferriprox-epar-risk-management-plan-summary_en.pdf"},{"key":"e_1_3_9_58_1","unstructured":"Dear healthcare professional letter - exjade. 2009."},{"key":"e_1_3_9_59_1","unstructured":"Ferriprox - important safety information. Available from: https:\/\/ferriprox.com\/hcp\/"},{"key":"e_1_3_9_60_1","unstructured":"Dear healthcare professional letter - Jadenu Canada. 2016."},{"key":"e_1_3_9_61_1","volume-title":"Drug bioavailability","author":"Price G","year":"2022","unstructured":"Price G, Patel DA. Drug bioavailability. Treasure Island (FL): StatPearls Publishing; 2022."},{"key":"e_1_3_9_62_1","doi-asserted-by":"publisher","DOI":"10.3109\/10915819409140653"},{"key":"e_1_3_9_63_1","unstructured":"EMA. Ferriprox [Internet]. cited 2024 Jun 20. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ferriprox#product-details"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2024.2386371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T08:16:36Z","timestamp":1776932196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2024.2386371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,3]]}},"alternative-id":["10.1080\/14740338.2024.2386371"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2024.2386371","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}